Oddo BHF Asset Management Sas Purchases Shares of 199,779 Astrazeneca Plc $AZN

Oddo BHF Asset Management Sas purchased a new stake in Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 199,779 shares of the company’s stock, valued at approximately $35,061,000. Astrazeneca accounts for about 1.3% of Oddo BHF Asset Management Sas’ holdings, making the stock its 15th biggest position.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership grew its holdings in shares of Astrazeneca by 552.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,547,597 shares of the company’s stock worth $973,603,000 after purchasing an additional 4,697,895 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Astrazeneca by 344.6% in the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after purchasing an additional 2,695,793 shares during the last quarter. Citigroup Inc. grew its holdings in shares of Astrazeneca by 65.3% in the 4th quarter. Citigroup Inc. now owns 6,154,760 shares of the company’s stock worth $1,080,160,000 after purchasing an additional 2,431,890 shares during the last quarter. Holocene Advisors LP grew its holdings in shares of Astrazeneca by 41.8% in the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after purchasing an additional 1,807,565 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of Astrazeneca by 11,190.9% in the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock worth $317,107,000 after purchasing an additional 1,790,874 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

NYSE AZN opened at $177.36 on Tuesday. The business has a 50 day simple moving average of $188.74 and a 200 day simple moving average of $186.10. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock has a market cap of $275.07 billion, a price-to-earnings ratio of 26.63, a PEG ratio of 1.55 and a beta of 0.25.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Analysts anticipate that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on AZN shares. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Weiss Ratings reissued a “buy (b)” rating on shares of Astrazeneca in a report on Monday, June 8th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a report on Tuesday, June 9th. Finally, TD Cowen reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.